https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48569 Wed 22 Mar 2023 15:26:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32180 .37 for interaction). Similarly, the treatment effects of low- vs standard-dose alteplase on function outcome (ordinal shift of the modified Rankin Scale) in Asians (odds ratio, 1.05; 95% CI, 0.90-1.22) was consistent with non-Asians (odds ratio, 0.93; 95% CI, 0.76-1.14) (P = .32 for interaction). There were generally consistent reductions in rates of symptomatic intracerebral hemorrhage with low-dose alteplase, although this reduction was not statistically significant by age, ethnicity, or severity. Conclusions and Relevance: This analysis found that the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability in key demographic subgroups of patients with AIS. Further investigation is required to identify patients with AIS who may benefit from low-dose alteplase. Trial Resgistration: clinicaltrials.gov Identifier: NCT01422616.]]> Thu 27 Jan 2022 15:56:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36807 Thu 04 Nov 2021 10:39:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45527 1c level of 5.7% to 6.4% or fasting plasma glucose level of 100 mg/dL to 125 mg/dL (to convert to mmol/L, multiply by 0.0555). Good adherence was defined as taking 80% or more of the protocol dose. Fasting glucose and hemoglobin A_1c, used to define prediabetes, and adherence of 80% or higher, stipulated in the protocol as defining good adherence, were prespecified subgroups in the analysis plan. Interventions: Participants were randomized to 15 mg of pioglitazone, with dose titrated to target of 45 mg daily, or matching placebo. Main Outcomes and Measures: The primary outcome was recurrent stroke or MI. Secondary outcomes included stroke, acute coronary syndrome, stroke/MI/hospitalization for heart failure, and progression to diabetes. Results: Among 3876 participants analyzed in the IRIS trial, 2885 were included in this analysis (1456 in the pioglitazone cohort and 1429 in the placebo cohort). The mean (SD) age of patients was 64 (11) years, and 974 (66.9%) and 908 (63.5%) of patients were men in the pioglitazone and placebo cohort, respectively. In the prediabetic population with good adherence (644 of 1456 individuals [44.2%] in the pioglitazone group and 810 of 1429 [56.7%] in the placebo group), the hazard ratios (95% CI) were 0.57 (0.39-0.84) for stroke/MI, 0.64 (0.42-0.99) for stroke, 0.47 (0.26-0.85) for acute coronary syndrome, 0.61 (0.42-0.88) for stroke/MI/hospitalization for heart failure, and 0.18 (0.10-0.33) for progression to diabetes. There was a nonsignificant reduction in overall mortality, cancer, and hospitalization, a slight increase in serious bone fractures, and an increase in weight gain and edema. Intention-to-treat results also showed significant reduction of events but to a lesser degree. Hazard ratios (95% CI) were 0.70 (0.56-0.88) for stroke/MI, 0.72 (0.56-0.92) for stroke, 0.72 (0.52-1.00) for acute coronary syndrome, 0.78 (0.63-0.96), for stroke/MI/hospitalization for heart failure, and 0.46 (0.35 to 0.61) for progression to diabetes. Conclusions and Relevance: Pioglitazone may be effective for secondary prevention in patients with stroke/transient ischemic attack and with prediabetes, particularly in those with good adherence. Trial Registration: ClinicalTrials.gov identifier: NCT00091949]]> Thu 03 Nov 2022 15:05:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41083 Fri 22 Jul 2022 17:11:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41084 Fri 22 Jul 2022 17:11:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52659 Fri 20 Oct 2023 09:09:41 AEDT ]]>